Ignite Creation Date:
2024-05-05 @ 7:17 PM
Last Modification Date:
2024-10-26 @ 9:46 AM
Study NCT ID:
NCT00634907
Status:
COMPLETED
Last Update Posted:
2017-06-08
First Post:
2008-02-06
Brief Title:
Prospective Genotyping For Total Hip or Knee Replacement Patients Receiving Warfarin Coumadin
Sponsor:
Gwen McMillin
Organization:
University of Utah
Study Overview
Official Title:
Prospective CYP2C9 And VKORC1 Genotyping For Total Hip or Knee Replacement Patients Receiving Warfarin CoumadinFor Anticoagulation
Status:
COMPLETED
Status Verified Date:
2017-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Several human genes affect how medications are metabolized by the body It is believed that knowledge of variations of these genes can help health care providers better manage an anticoagulation medicine called warfarin Coumadinand as a result decrease patient problems with bleeding or the development of blood clots This study was designed to evaluate if genetic testing can improve warfarin initiation better than usual care
Detailed Description:
This study was completed in 2008 and was published Consult the citation link for more details
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None